Bone health and prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 1, 2010, Pages 20-27

  Saylor, P J ^a   Smith, M R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bisphosphonate; Bone metastases; Denosumab; Osteoclast; Skeletal related events; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORHEXIDINE; CLODRONIC ACID; CORTICOTROPIN RELEASING FACTOR AGONIST; DENOSUMAB; ETIDRONIC ACID; GLUCOCORTICOID; I KAPPA B KINASE; IBANDRONIC ACID; LACTATE DEHYDROGENASE; MITOXANTRONE; NERIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; TOREMIFENE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ALGORITHM; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE EROSION; BONE METASTASIS; BONE NECROSIS; BONE TURNOVER; CANCER GROWTH; CANCER MORTALITY; CANCER PAIN; CELL ACTIVATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG POTENCY; FLU LIKE SYNDROME; FLUSHING; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; NAUSEA; NEPHROTOXICITY; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SPINAL CORD COMPRESSION; TARGET CELL; TRABECULAR BONE; TREATMENT RESPONSE; VOMITING;

ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; IMIDAZOLES; MALE; OSTEOCLASTS; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 76949090950     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.50     Document Type: Review

References (73)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
2. Clarke NW, McClure J, George NJ. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993; 24: 286-290. (Pubitemid 23246064)
3. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88 (12 Suppl): 2919-2926.
4. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ et al. Markers of bone metabolism and survival in men with hormonerefractory metastatic prostate cancer. Clin Cancer Res 2006; 12 (11 Pt 1): 3361-3367.
5. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066.
6. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
7. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-2367; discussion 7.
8. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
9. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-1566.
10. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-1222.
11. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
12. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
13. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
14. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903.
15. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-139; discussion 9.
16. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14: 1468-1476.
17. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96: 133-138.
18. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007; 1117: 209-257.
19. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
20. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial- the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150-3157.
21. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882. (Pubitemid 38807610)
23. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-4284.
24. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201.
25. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/ prednisone and placebo in patients with hormonerefractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-3342.
26. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95: 1300-1311.
27. Dearnaley D, Mason MD, Parmar M, Sanders K, Sydes MR. Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: long-term results of MRC PR04 & PR05. In: Genitourinary Cancers Symposium; 2009: American Society of Clinical Oncology.
28. Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99: 765-776.
29. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL et al. Natural history of rising serum prostatespecific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925.
30. Major PP, Cook RJ, Chen BL, Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005; 2: 234-240.
31. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389-406.
32. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-289.
33. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-1679; discussion 9.
34. Novartis. Zometa full prescribing information. Package insert; 2008.
35. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
36. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
37. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.
38. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65: 1328-1331.
39. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-836.
40. Vescovi P, Manfredi M, Merigo E, Meleti M. Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2008; 66: 831-832.
41. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-831.
42. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882.
43. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M et al. A study of the biological receptor activator of nuclear factorkappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
44. Saad F, Smith MR, Egerdie B, Tammela TL, Feldman RA, Heracek J et al. Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC). In: ASCO Annual Meeting; Orlando, 2009.
45. US Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, MD. US Department of Health and Human Services, Office of Surgeon General, 2004.
46. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7: 407-413.
47. Jiang HX, Majumdar SR, Dick DA, Moreau M, Raso J, Otto DD et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005; 20: 494-500.
48. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999; 84: 3431-3434.
49. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-106.
50. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827.
51. Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E. Bone fragility in men-where are we? Osteoporos Int 2006; 17: 1577-1583.
52. De Laet C, Oden A, Johansson H, Johnell O, Jonsson B, Kanis JA. The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 2005; 16: 313-318.
53. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30: 251-258.
54. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581-589.
55. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397.
56. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P et al. Body mass index as a predictor of fracture risk: a metaanalysis. Osteoporos Int 2005; 16: 1330-1338.
57. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20: 1185-1194.
58. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16: 737-742.
59. Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA et al. A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 2005; 16: 799-804.
60. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA et al. A family history of fracture and fracture risk: a metaanalysis. Bone 2004; 35: 1029-1037.
61. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-899. (Pubitemid 41103445)
62. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375-382. (Pubitemid 38953182)
63. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005; 16: 155-162.
64. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-424.
65. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
66. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebocontrolled crossover study. Cancer 2001; 92: 1444-1450.
67. Smith MR, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
68. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042.
69. Morabito N, Gaudio A, Lasco A, Catalano A, Atteritano M, Trifiletti A et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 2004; 19: 1766-1770.
70. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-3846.
71. Steiner MS, Patterson A, Israeli R, Barnette KG, Boger R, Price D. Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer. Proc ASCO (abstract 4597) 2004.
72. Smith MR, Ellis GK, Saad F, Tammela TL, Bone HG, Egerdie B et al. Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. In: ASCO Annual Meeting; Orlando, 2009.
73. Smith MR, Morton RA, Malkowicz B, Wallace H, Rodriguez D, Hancock M et al. A phase III randomized controlled trial of toremifene to prevent fractures and other adverse effects of androgen deprivation therapy in men with prostate cancer. In: AACR Annual Meeting; San Diego, CA, 2009.